- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-Centered Diabetes Care of Cancer Patients
Authors
Keywords
-
Journal
Current Diabetes Reports
Volume 21, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-13
DOI
10.1007/s11892-021-01435-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
- (2021) V. Lo Preiato et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism
- (2021) Diane Mourad et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
- (2021) Kaori Hisanaga et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
- (2021) Imke Grimmelmann et al. EUROPEAN JOURNAL OF CANCER
- Endocrine toxicities of immune checkpoint inhibitors
- (2021) Jordan J. Wright et al. Nature Reviews Endocrinology
- Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study
- (2021) Marie Bastin et al. THERAPIE
- Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
- (2021) Amy L. Zhang et al. Frontiers in Endocrinology
- A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital
- (2021) Felix Aberer et al. Journal of Clinical Medicine
- Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management
- (2021) Anupam Kotwal Current Opinion in Endocrinology Diabetes and Obesity
- Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
- (2020) Z. Quandt et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Diabetes Technology in the Inpatient Setting for Management of Hyperglycemia
- (2020) Georgia M. Davis et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Acquired lipodystrophy associated with immune checkpoint inhibitors
- (2020) Subashini S. Gnanendran et al. MELANOMA RESEARCH
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
- (2020) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
- (2020) Zoe Quandt et al. Annual Review of Medicine
- Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
- (2020) Nicola Silvestris et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
- (2020) Misty Shields et al. Oncotarget
- 12. Older Adults: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- Challenges in the management of people with diabetes and cancer
- (2019) T. A. Chowdhury et al. DIABETIC MEDICINE
- T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors
- (2019) Sho Yoneda et al. DIABETES CARE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab
- (2019) Beckey Trinh et al. DIABETES CARE
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes
- (2019) Venessa H M Tsang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
- (2019) Anupam Kotwal et al. THYROID
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
- (2018) Romualdo Barroso-Sousa et al. CANCER
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis
- (2018) Jetty A. Overbeek et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment
- (2018) Jonathan Pearson-Stuttard et al. Lancet Diabetes & Endocrinology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring
- (2017) Yusuke Yata et al. INTERNAL MEDICINE
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies
- (2016) Jennifer W. Wu et al. DIABETES CARE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
- (2016) Jonathan W. Goldman et al. ONCOLOGIST
- Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
- (2016) Khurum H. Khan et al. ONCOLOGIST
- A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients
- (2016) Yusook Jeong et al. Cancer Research and Treatment
- Diabetes and mortality in patients with prostate cancer: a meta-analysis
- (2016) Junga Lee et al. SpringerPlus
- Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes
- (2015) R. Fujisawa et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus
- (2015) Valentina Perri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
- (2014) Rahul Aggarwal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hyperglycemia, a Neglected Factor during Cancer Progression
- (2014) Wanxing Duan et al. Biomed Research International
- Glucocorticoid-induced hyperglycemia (糖皮质激素诱导的高血糖)
- (2013) Antonio Perez et al. Journal of Diabetes
- The Links Between Insulin Resistance, Diabetes, and Cancer
- (2012) Etan Orgel et al. Current Diabetes Reports
- Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms
- (2012) Biagio Arcidiacono et al. Experimental Diabetes Research
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes
- (2011) Fumitaka Haseda et al. IMMUNOLOGY LETTERS
- Diabetes and Cancer: A Consensus Report
- (2010) E. Giovannucci et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Insulin-Mediated Acceleration of Breast Cancer Development and Progression in a Nonobese Model of Type 2 Diabetes
- (2010) R. Novosyadlyy et al. CANCER RESEARCH
- Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase
- (2010) L Zeng et al. ENDOCRINE-RELATED CANCER
- Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden
- (2009) J. M. Jonasson et al. DIABETOLOGIA
- Glucocorticoid-Induced Hyperglycemia
- (2009) John Clore et al. Endocrine Practice
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started